Search results
The Molecular Biology Department at Colombia’s Laboratorio Clinico Medico Colcan is using a Freedom EVO® 150 liquid handling platform to automate its nucleic acid extraction and real-time PCR protocols, offering increased flexibility and helping to improve sample throughput.
- Freedom EVO Packages
Freedom EVO ® packages. The Freedom EVO series is one of the...
- Read More
Freedom EVOware is the driving force behind every...
- Scientific Citations
All working concentrations of 2, 10, and 50 ÂľM, were...
- Consumables
Consumables Assured performance. At Tecan, we work...
- Spark
Tecan’s Spark multimode reader has an integrated, bright...
- SelectScience
Independent Product Reviews - Freedom EVO series. Tecan...
- Freedom EVO Brochure
Freedom EVO brochure . Fully automated liquid handling and...
- Mio
This website stores Cookies on your device. These Cookies...
- Freedom EVO Packages
Infinite® F50 How To Infinite® F50 Trouble Shooting Infinite® 200 Pro How To Infinite® 200Pro Tips & Tricks
Freedom EVO 150 | The Tecan Journal is published several times a year, and contains articles featuring users of Tecan instruments, as well as information about latest products and global Tecan activities.
DETAILED INFO AND PHOTOS FOR THIS & SIMILAR ITEMS MAY BE FOUND AT https://www.bostonind.com/laboratory/automated-liquid-handling-systems-and-robotics/large-l...
To create a new tube robot vector, right-click the group heading Robot Vectors (Tubes), choose New, enter a descriptive name of your choice and click OK to open the Teach Tube Robot Vector dialog box (see 9.7.2 “Teach Tube Robot Vector Dialog Box”, 2 9-65). Use the name “Home1” to create a home vector for tube robot 1.
Independent Product Reviews - Freedom EVO series. Tecan Freedom EVO series - SelectScience - Independent Product Reviews.
This next generation LB-MSIA workflow for Freedom EVO platform demonstrated percent coeficients of variation (% CV) and sensitivity akin to a traditional ligand binding assay for adalimumab (Humira®), infliximab (Remicade®), denosumab (Prolia®), natalizumab (Tysabri®) and trastuzumab (Herceptin®).